José María founded PharmaMar in 1986 and is currently the Chairman of the Board of Directors and Executive President.
He has been a Professor of Biochemistry at the Complutense University of Madrid and the University of Santiago de Compostela, he obtained an MBA from the IESE Business School in Madrid. Dr. Fernández Sousa-Faro has over 90 scientific articles and patents in the field of biochemistry, drug discovery and molecular biology. With more than 35 years of experience in the pharmaceutical industry, he has held positions within the executive management of ICI-Farma, Antibióticos, Zeltia and PharmaMar.
He was a member of the Board of Directors of Antibiotics, Penibérica, Biolys, ICI-Farma, Pescanova, Transfesa, Cooper–Zeltia, ICI-Zeltia and Banco Guipuzcoano.
With 30 years’ experience in the pharmaceutical industry and a Degree in Business Administration from the University of Barcelona, Luis Mora began his career as the Financial Controller for Zambon, S.A. and Pharmazam, S.A. in Barcelona and later as Head of Finance for Zambón Portugal. From 1995-2000 he served as Financial Controller with the Antibióticos Group (Montedison), and as Board Member of Vitatene, in Milan, Italy. He joined PharmaMar in 2000 as Chief Financial Officer and was appointed Managing Director in 2008, presiding over the unit through Yondelis®, Aplidin® and ZepzelcaTM approvals in various countries including those regulated by FDA and EMA.
Ms. De Francia has been with PharmaMar and its predecessor Zeltia since 1988 holding various positions in the finance department, and becoming the Chief Financial Officer of Zeltia in 2000, and then for PharmaMar since the PharmaMar-Zeltia merger in 2015. Ms. de Francia holds an undergraduate degree in law, as well as a graduate degree in Business Administration from the Universidad Pontifical Comillas (ICADE) de Madrid. She also is a member of the Board of Directors for GENOMICA subsidiary.
Juan Gómez Pulido is currently General Counsel and Secretary of the Board of Directors of Pharma Mar, being responsible for all the company’s corporate legal matters, since July 2019. Since joining Zeltia in January 2013, and later in Pharma Mar, he has been Senior Legal Counsel of the Legal Department of the Group. Previously, Mr. Gómez Pulido was a Senior Associate of the Corporate and M&A Department of Ramón y Cajal Abogados, a Madrid-based law firm, as well as an Associate of the corporate department of other national and international law firms. Mr. Gómez Pulido holds a Law Degree from the Pontificia University of Comillas (ICADE E-1) and a Master’s Degree in Corporate Law from IE Business School.
Sandra Llamera joined PharmaMar as Global Compliance Head in 2020, after a dilated experience in the pharma industry.
Since 2018, she has been a member of the Board of Directors of the Institute of Compliance Officers, starting while at Teva as Director of Compliance for Spain/Portugal. She implemented the compliance programs at the factory and logistics center in Spain, led the adaptation to the new European Data Protection Regulation (GDPR), and actively participated in the design and implementation of the global compliance program imposed by the US Department of Justice.
Sandra began her career at Pfizer, serving in both the legal and compliance departments amongst others, for 12 years. She was involved in anti-corruption policies, FCPA regulations, clinical trial monitoring, drug promotion policies, competitive practices and audits, among others
She has a degree in Law from the San Paulo CEU University and has been a speaker at various professional courses and conferences.
Mr. Moreno has been the Director of Capital Markets and Investor Relations at PharmaMar since 2009. From 2002 until 2009, he was the co-founder and managing partner of the independent financial group Solventis. He previously headed equity sales at Banco Espirito Santo Investment for three years after holding the same position at Benito y Monjardín SVB. He started his career in 1994 working in the research and marketing department of the Spanish Futures and Options Exchange developing financial derivatives.
Mr. Moreno graduated with a degree in Management and Business Administration from the University of Hertfordshire and has a degree in Business Administration from the University of Barcelona. He has an executive management program (PDG) from IESE and is also a Chartered Alternative Investment Analyst (CAIA). He has taught Masters courses on financial derivative products offered by the University of Barcelona, as well as other related courses at the Abat Oliba CEU University, the Center for Financial Studies and MEFF.
José Luis received his Master’s degree in Biochemistry from the Complutense University of Madrid. He has experience in Quality related issues since 1986 and, in particular, in different management positions within the pharmaceutical industry since 1990 (for example Bristol-Myers, DSM Deretil and Justesa Imagen S.A). He is also an expert in DuPont’sTM STOP® safety methodology.
He has worked at the Spanish National Accreditation Body (ENAC), and as a Quality consultant. He joined PharmaMar in 2004 as the Director of the Quality Unit. He oversees and manages all aspects of GxP Quality Functions.
Ms. Sanz is currently Director of the business area in the Legal Department of PharmaMar, a position she has held since July 2019. Ms. Sanz joined PharmaMar in 2007 as Legal Advisor, and in 2015 she was appointed as vice-secretary of the Board of Directors at PharmaMar. Previously, she was an Associate at the Elzaburu law firm.
Ms. Sanz has a Law Degree from the Pontificia University of Comillas (ICADE E-1) and a Master’s Degree in Intellectual Property (Magister Lvcentinvs) from the University of Alicante.
With a Master’s in Financial Management from ESIC, he joined the PharmaMar Group’s Finance team in May 1989. Since November 2011, he has been in charge of the Group’s Internal Audit department, supervising the internal control system for financial reporting. He was previously Chief Accountant at Zeltia (June 2002–Nov. 2011) and at PharmaMar (Nov. 1994-June 2002), also collaborating with the Group’s other subsidiaries.